Skip to main content
. 2019 Aug 7;18(4):3914–3924. doi: 10.3892/ol.2019.10731

Figure 3.

Figure 3.

The percentage of circulating immature and granulocytic MDSCs in gBRCAm and BRCAwt HGSOC (Cohort 1). (A) The percentage of immature MDSCs was lower in gBRCAm HGSOC (n=25) compared with BRCAwt HGSOC (n=16; P=0.048). (B and C) The difference of immature MDSCs between gBRCAm (n=12) and BRCAwt (n=10) samples was not seen in those <5 years from initial diagnosis (P=0.16), or in those ≥5 years from initial diagnosis (P=0.24). Percentage of granulocytic MDSCs was not different between (D) gBRCAm and BRCAwt HGSOC (P=0.34), or (E) in those <5 years from initial diagnosis (P=0.68), or (F) in those ≥5 years from initial diagnosis (P=0.58). The ratio of (G) lin- and (H) monocytic MDSCs to CD8+ T cells were lower in gBRCAm (P=0.007 and P=0.009, respectively). The dotted lines represent the median values. MDSCs, myeloid-derived suppressor cells; gBRCAm, germline BRCA mutation; BRCAwt, germline BRCA wild-type; HGSOC, high grade serous ovarian carcinoma.